Hostname: page-component-848d4c4894-4rdrl Total loading time: 0 Render date: 2024-06-23T22:05:40.448Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1275 – Agomelatine as Monotherapy in Depression

Published online by Cambridge University Press:  15 April 2020

E. Tzavellas ,
D. Karaiskos ,
K. Tzavella ,
I. Liappas  and
T. Paparrigopoulos
E. Tzavellas
Affiliation:
Department of Psychiatry, Eginition Hospital of Athens, Athens, Greece
D. Karaiskos
Affiliation:
Department of Psychiatry, Eginition Hospital of Athens, Athens, Greece
K. Tzavella
Affiliation:
Internal Medicine, Private, Munich, Germany
I. Liappas
Affiliation:
Department of Psychiatry, Eginition Hospital of Athens, Athens, Greece
T. Paparrigopoulos
Affiliation:
Department of Psychiatry, Eginition Hospital of Athens, Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Agomelatine is an melatonergic antidepressant marketed for the treatment of major depressive disorder and has been reported to have a reduced level of sexual side effects as well as discontinuation effects.

The present study examined the efficacy of agomelatine in the treatment of symptoms of depression/anxiety in a sample of depressed patients.

Method:

110 patients who fulfilled the DSM-IV diagnostic criteria for a major depressive episode treated on an outpatient basis at the Eginition Hospital were assessed with the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale and the Global Assessment Functioning. The questionnaires were administered at the beginning of the medication period and thereafter every week over a 6-week period. Descriptive statistics are used for the presentation of the results.

Results:

Mean age ± SD of the sample was 52.5 ± 9,3 years. Mean score ± SD on the HDRS, HARS and GAF at the different time points of assessment are shown below.

Baseline (1) 1st week (2) 2nd week (3) 3rd week (4) 4th week (5) 5th week(6)

(mean±SD) (mean±SD) (mean±SD) (mean±SD) (mean±SD) (mean±SD)

HDRS 37.2±2.4 32.5±1.8 28.4±2.6 14.4±2.8 6.8±2.6 6.1±1.8

HARS 34.6±7.7 32.3±1.4 27.3±2.5 14.2±2.1 6.4±1.8 6.2±2.1

GAF 45.6±8.2 47.1±2.2 57.7±2.1 72.2±2.1 88.5±2.4 91.1±1.7

Psychopathology significantly subsided by the end of the study period; improvement was marked already from the third week of treatment.

Conclusion:

The main finding of the present study was that monotherapy with agomelatine had a positive effect on symptoms of depression, anxiety, and global functioning in depressed patients.

Type
E04 - e-Poster Oral Session 04: Therapy and Consultant liaison psychiatry, miscellaneous
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.